Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR)

References

1. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quirós JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105–20. Erratum in: N Engl J Med 2010;362:2433.Search in Google Scholar

2. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011;378: 804–14.10.1016/S0140-6736(11)60813-1Search in Google Scholar

3. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548–56.10.1210/jc.2004-0395Search in Google Scholar PubMed

4. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 2005;64:163–9.10.1079/PNS2005428Search in Google Scholar

5. Schäffler A, Müller-Ladner U, Schölmerich J, Büchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006;27:449–67.10.1210/er.2005-0022Search in Google Scholar PubMed

6. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772–83.10.1038/nri1937Search in Google Scholar PubMed

7. Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res 2007;75:690–701.10.1016/j.cardiores.2007.03.008Search in Google Scholar PubMed

8. Eringa EC, Bakker W, Smulders YM, Serné EH, Yudkin JS, Stehouwer CD. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 2007;14:389–402.10.1080/10739680701303584Search in Google Scholar PubMed

9. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerbäck S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518–25. Erratum in: N Engl J Med 2009;361:1123.Search in Google Scholar

10. Bjørndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes 2011;2011:490650.10.1155/2011/490650Search in Google Scholar PubMed PubMed Central

11. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med 2013;19:1252–63.10.1038/nm.3361Search in Google Scholar PubMed

12. Giralt M, Villarroya F. White, brown, beige/brite: different adipose cells for different functions? Endocrinology 2013;154:2992–3000.10.1210/en.2013-1403Search in Google Scholar PubMed

13. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999;7:355–62.10.1002/j.1550-8528.1999.tb00418.xSearch in Google Scholar PubMed

14. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, Hamet P, Pausova Z, Gaudet D, Gossard F, Kotchen TA. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001;37:845–50.10.1161/01.HYP.37.3.845Search in Google Scholar

15. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005;45:356–62.10.1161/01.HYP.0000154361.47683.d3Search in Google Scholar PubMed

16. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in hYpertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008;93:2566–71.10.1210/jc.2008-0251Search in Google Scholar PubMed

17. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008;19:88–90.10.1016/j.tem.2008.01.006Search in Google Scholar PubMed

18. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010;12:252–7.10.1007/s11906-010-0126-2Search in Google Scholar PubMed PubMed Central

19. Iacobellis G, Sharma AM. Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 2007;13:2180–4.10.2174/138161207781039670Search in Google Scholar PubMed

20. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 2009;104:541–9.10.1161/CIRCRESAHA.108.182998Search in Google Scholar PubMed PubMed Central

21. Rajsheker S, Manka D, Blomkalns AL, Chatterjee TK, Stoll LL, Weintraub NL. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol 2010;10:191–6.10.1016/j.coph.2009.11.005Search in Google Scholar PubMed PubMed Central

22. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertension 1991;13:277–96.Search in Google Scholar

23. Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J 2002;16:1057–63.10.1096/fj.02-0024comSearch in Google Scholar PubMed

24. Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, Gollasch M. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 2004;44: 271–6.10.1161/01.HYP.0000140058.28994.ecSearch in Google Scholar

25. Dubrovska G, Verlohren S, Luft FC, Gollasch M. Mechanisms of ADRF release from rat aortic adventitial adipose tissue. Am J Physiol 2004;286:H1107–13.10.1152/ajpheart.00656.2003Search in Google Scholar

26. Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 2007;151:323–31.10.1038/sj.bjp.0707228Search in Google Scholar

27. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009;119:1661–70.10.1161/CIRCULATIONAHA.108.821181Search in Google Scholar

28. Le Bacquer O, Petroulakis E, Paglialunga S, Poulin F, Richard D, Cianflone K, Sonenberg N. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007;117:387–96.10.1172/JCI29528Search in Google Scholar

29. Ma L, Ma S, He H, Yang D, Chen X, Luo Z, Liu D, Zhu Z. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res 2010;33:446–53.10.1038/hr.2010.11Search in Google Scholar

30. Fernández-Alfonso MS, Gil-Ortega M, García-Prieto CF, Aranguez I, Ruiz-Gayo M, Somoza B. Mechanisms of perivascular adipose tissue dysfunction in obesity. Int J Endocrinol 2013;2013:402053.10.1155/2013/402053Search in Google Scholar

31. Gil-Ortega M, Condezo-Hoyos L, García-Prieto CF, Arribas SM, González MC, Aranguez I, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Imbalance between pro and anti-oxidant mechanisms in perivascular adipose tissue aggravates long-term high-fat diet-derived endothelial dysfunction. PLoS One 2014;9:e95312.10.1371/journal.pone.0095312Search in Google Scholar

32. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signaling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817–20.10.1016/S0140-6736(05)66585-3Search in Google Scholar

33. Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med 2011;9:25.10.1186/1741-7015-9-25Search in Google Scholar PubMed PubMed Central

34. Szasz T, Bomfim GF, Webb RC. The influence of perivascular adipose tissue on vascular homeostasis. Vasc Health Risk Manag 2013;9:105–16.10.2147/VHRM.S33760Search in Google Scholar PubMed PubMed Central

35. Schleifenbaum J, Köhn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, Crean CS, Luft FC, Huang Y, Schubert R, Gollasch M. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens 2010;28:1875–82.10.1097/HJH.0b013e32833c20d5Search in Google Scholar PubMed

36. Xi W, Satoh H, Kase H, Suzuki K, Hattori Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 2005;332:200–5.10.1016/j.bbrc.2005.04.111Search in Google Scholar PubMed

37. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, Gollasch M. Adiponectin is a novel humoral vasodilator. Cardiovasc Res 2007;75:719–27.10.1016/j.cardiores.2007.05.025Search in Google Scholar PubMed

38. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008;114:361–74.10.1042/CS20070347Search in Google Scholar PubMed

39. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010;393:668–72.10.1016/j.bbrc.2010.02.053Search in Google Scholar PubMed

40. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011;19:1552–9.10.1038/oby.2010.351Search in Google Scholar PubMed

41. Bełtowski J. Apelin and visfatin: unique “beneficial” adipokines upregulated in obesity? Med Sci Monit 2006;12:RA112–9.Search in Google Scholar

42. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun 2009;383:503–8.10.1016/j.bbrc.2009.04.074Search in Google Scholar PubMed

43. Vallejo S, Romacho T, Angulo J, Villalobos LA, Cercas E, Leivas A, Bermejo E, Carraro R, Sánchez-Ferrer CF, Peiró C. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One 2011;6:e27299.10.1371/journal.pone.0027299Search in Google Scholar PubMed PubMed Central

44. Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010;15:225–9.10.1111/j.1440-1797.2009.01173.xSearch in Google Scholar PubMed

45. Ketonen J, Shi J, Martonen E, Mervaala E. Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57Bl/6 mice. Circ J 2010;74:1479–87.10.1253/circj.CJ-09-0661Search in Google Scholar PubMed

46. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RM. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 2006;71:363–73.10.1016/j.cardiores.2006.03.013Search in Google Scholar PubMed

47. Knock GA, Snetkov VA, Shaifta Y, Connolly M, Drndarski S, Noah A, Pourmahram GE, Becker S, Aaronson PI, Ward JP. Superoxide constricts rat pulmonary arteries via Rho-kinase-mediated Ca2+ sensitization. Free Radic Biol Med 2009;46:633–42.10.1016/j.freeradbiomed.2008.11.015Search in Google Scholar PubMed PubMed Central

48. Gao YJ, Hirota S, Zhang DW, Janssen LJ, Lee RM. Mechanisms of hydrogen-peroxide-induced biphasic response in rat mesenteric artery. Br J Pharmacol 2003;138:1085–92.10.1038/sj.bjp.0705147Search in Google Scholar PubMed PubMed Central

49. Gil-Longo J, González-Vázquez C. Characterization of four different effects elicited by H2O2 in rat aorta. Vascul Pharmacol 2005;43:128–38.10.1016/j.vph.2005.06.001Search in Google Scholar PubMed

50. Marvar PJ, Hammer LW, Boegehold MA. Hydrogen peroxide-dependent arteriolar dilation in contracting muscle of rats fed normal and high salt diets. Microcirculation 2007;14:779–91.10.1080/10739680701444057Search in Google Scholar PubMed

51. Rahmouni K, Haynes WG. Endothelial effects of leptin: implications in health and diseases. Curr Diab Rep 2005;5:260–6.10.1007/s11892-005-0020-5Search in Google Scholar PubMed

52. Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El Gamel A, Desai JB, Nelson T, Driver C, Sherwood RA, Kearney MT. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J 2006;27:2294–9.10.1093/eurheartj/ehi831Search in Google Scholar PubMed

53. Mohammed MM, Myers DS, Sofola OA, Hainsworth R, Drinkhill MJ. Vasodilator effects of leptin on canine isolated mesenteric arteries and veins. Clin Exp Pharmacol Physiol 2007;34:771–4.10.1111/j.1440-1681.2007.04648.xSearch in Google Scholar PubMed

54. Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 2011;58:271–9.10.1161/HYPERTENSIONAHA.110.168427Search in Google Scholar PubMed PubMed Central

55. Beltowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clin Exp Pharmacol Physiol 2012;39:168–78.10.1111/j.1440-1681.2011.05623.xSearch in Google Scholar PubMed

56. Zhang DX, Yi FX, Zou AP, Li PL. Role of ceramide in TNF-α-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. Am J Physiol Heart Circ Physiol 2002;283:H1785–94.10.1152/ajpheart.00318.2002Search in Google Scholar PubMed

57. Wort SJ, Ito M, Chou PC, Mc Master SK, Badiger R, Jazrawi E, de Souza P, Evans TW, Mitchell JA, Pinhu L, Ito K, Adcock IM. Synergistic induction of endothelin-1 by tumor necrosis factor α and interferon γ is due to enhanced NF-κB binding and histone acetylation at specific κB sites. J Biol Chem 2009;284:24297–305.10.1074/jbc.M109.032524Search in Google Scholar PubMed PubMed Central

58. Ohkawa F, Ikeda U, Kawasaki K, Kusano E, Igarashi M, Shimada K. Inhibitory effect of interleukin-6 on vascular smooth muscle contraction. Am J Physiol 1994;266:H898–902.10.1152/ajpheart.1994.266.3.H898Search in Google Scholar PubMed

59. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II-induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 2007;27:2576–81.10.1161/ATVBAHA.107.153080Search in Google Scholar PubMed

60. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [125I]-(Pyr1) Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132:1255–60.10.1038/sj.bjp.0703939Search in Google Scholar PubMed PubMed Central

61. Kagiyama S, Fukuhara M, Matsumura K, Lin YZ, Fuji K, Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 2005;125:55–9.10.1016/j.regpep.2004.07.033Search in Google Scholar PubMed

62. Salcedo A, Garijo J, Monge L, Fernández N, García-Villalón AL, Sánchez Turrión V, Cuervas-Mons V, Diéguez G. Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept 2007;144:50–5.10.1016/j.regpep.2007.06.005Search in Google Scholar PubMed

63. Japp AG, Newby DE. The apelin-APJ system in heart failure. pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008;75:1882–92.10.1016/j.bcp.2007.12.015Search in Google Scholar PubMed

64. Ceylan-Isik AF, Kandadi MR, Xu X, Hua Y, Chicco AJ, Ren J, Nair S. Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol 2013;63:4–13.10.1016/j.yjmcc.2013.07.002Search in Google Scholar PubMed

65. Zhang CH, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003;92:322–9.10.1161/01.RES.0000056759.53828.2CSearch in Google Scholar PubMed

66. Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: the role of adipocyte-derived angiotensin II. Eur J Pharmacol 2010;634:107–12.10.1016/j.ejphar.2010.02.006Search in Google Scholar PubMed

67. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932–9.10.1161/01.CIR.0000155620.10387.43Search in Google Scholar PubMed

68. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, Antenucci G, Maffei A, Cifelli G, Iorio L, Landolfi A, Frati G, Lembo G. Resistin impairs insulin-evoked vasodilation. Diabetes 2008;57:577–83.10.2337/db07-0557Search in Google Scholar PubMed

69. Lobato NS, Neves KB, Filgueira FP, Fortes ZB, Carvalho MH, Webb RC, Oliveira AM, Tostes RC. The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the MEK-ERK1/2 pathway. Life Sci 2012;91:600–6.10.1016/j.lfs.2012.04.013Search in Google Scholar PubMed

70. Watts SW, Dorrance AM, Penfold ME, Rourke JL, Sinal CJ, Seitz B, Sullivan TJ, Charvat TT, Thompson JM, Burnett R, Fink GD. Chemerin connects fat to arterial contraction. Arterioscler Thromb Vasc Biol 2013;33:1320–8.10.1161/ATVBAHA.113.301476Search in Google Scholar PubMed PubMed Central

71. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011;34:307–10.10.1248/bpb.34.307Search in Google Scholar PubMed

72. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC. Chemerin reduces vascular nitric oxide/cGMP signaling in rat aorta: a link to vascular dysfunction in obesity? Clin Sci (Lond) 2014;127:111–22.10.1042/CS20130286Search in Google Scholar PubMed

73. Payne GA, Borbouse L, Bratz IN, Roell WC, Bohlen HG, Dick GM, Tune JD. Endogenous adipose-derived factors diminish coronary endothelial function via inhibition of nitric oxide synthase. Microcirculation 2008;15:417–26.10.1080/10739680701858447Search in Google Scholar PubMed PubMed Central

74. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752–61.10.1172/JCI21625Search in Google Scholar PubMed PubMed Central

75. Aroor AR, Mandavia C, Ren J, Sowers JR, Pulakat L. Mitochondria and oxidative stress in the cardiorenal metabolic syndrome. Cardiorenal Med 2012;2:87–109.10.1159/000335675Search in Google Scholar PubMed PubMed Central

76. Whaley-Connell A, Sowers JR. Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep 2012;14:360–5.10.1007/s11906-012-0279-2Search in Google Scholar PubMed PubMed Central

77. Kobayasi R, Akamine EH, Davel AP, Rodrigues MA, Carvalho CR, Rossoni LV. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet-induced obesity in mice. J Hypertens 2010;28:2111–9.10.1097/HJH.0b013e32833ca68cSearch in Google Scholar PubMed

78. Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X, Huang Y. Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res 2012;110:1211–6.10.1161/CIRCRESAHA.111.262170Search in Google Scholar PubMed

79. Schäfer N, Lohmann C, Winnik S, van Tits LJ, Miranda MX, Vergopoulos A, Ruschitzka F, Nussberger J, Berger S, Lüscher TF, Verrey F, Matter CM. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J 2013;34:3515–24.10.1093/eurheartj/eht095Search in Google Scholar PubMed PubMed Central

80. Potenza MA, Gagliardi S, Nacci C, Carratu’ MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009;16:94–112.10.2174/092986709787002853Search in Google Scholar PubMed

81. Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci 2013;14:21525–50.10.3390/ijms141121525Search in Google Scholar PubMed PubMed Central

82. Otani H. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 2011;15:1911–26.10.1089/ars.2010.3739Search in Google Scholar PubMed

83. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999;104:447–57.10.1172/JCI5971Search in Google Scholar PubMed PubMed Central

84. McCarty MF. Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. Med Hypotheses 2010;75:276–81.10.1016/j.mehy.2009.12.027Search in Google Scholar PubMed

85. Inoguchi T, Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 2005;6:495–501.10.2174/1389450054021927Search in Google Scholar PubMed

86. Payne GA, Bohlen HG, Dincer UD, Borbouse L, Tune JD. Periadventitial adipose tissue impairs coronary endothelial function via PKC-beta-dependent phosphorylation of nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009;297:H460–5.10.1152/ajpheart.00116.2009Search in Google Scholar PubMed PubMed Central

87. Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res 2013;10:472–82.10.1177/1479164113500680Search in Google Scholar PubMed

88. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454–6.10.1038/320454a0Search in Google Scholar PubMed

89. Thengchaisri N, Kuo L. Hydrogen peroxide induces endothelium dependent and -independent coronary arteriolar dilation: role of cyclooxygenase and potassium channels. Am J Physiol Heart Circ Physiol 2003;285:H2255–63.10.1152/ajpheart.00487.2003Search in Google Scholar PubMed

90. Lucchesi PA, Belmadani S, Matrougui K. Hydrogen peroxide acts as both vasodilator and vasoconstrictor in the control of perfused mouse mesenteric resistance arteries. J Hypertens 2005;23:571–9.10.1097/01.hjh.0000160214.40855.79Search in Google Scholar PubMed

91. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) 2006;231:237–51.10.1177/153537020623100302Search in Google Scholar PubMed

92. Moreno JM, Rodriguez Gomez I, Wangensteen R, Perez-Abud R, Duarte J, Osuna A, Vargas F. Mechanisms of hydrogen peroxide-induced vasoconstriction in the isolated perfused rat kidney. J Physiol Pharmacol 2010;61:325–32.Search in Google Scholar

93. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 2009;302:111–7.10.1016/j.mce.2009.01.019Search in Google Scholar PubMed PubMed Central

94. Zennaro MC, Caprio M, Fève B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 2009;20:444–51.10.1016/j.tem.2009.05.006Search in Google Scholar PubMed

95. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010;52:401–9.10.1016/j.pcad.2009.12.004Search in Google Scholar PubMed PubMed Central

96. Stiefel P, Vallejo-Vaz AJ, García Morillo S, Villar J. Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011;2011:685238.10.4061/2011/685238Search in Google Scholar PubMed PubMed Central

97. Ronconi V, Turchi F, Appolloni G, di Tizio V, Boscaro M, Giacchetti G. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr Vasc Pharmacol 2012;10:238–46.10.2174/157016112799304969Search in Google Scholar PubMed

98. Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res 2013;50:89–99.10.1159/000345243Search in Google Scholar PubMed

99. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998;24:789–96.10.3109/07435809809032689Search in Google Scholar PubMed

100. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007;30:2349–54.10.2337/dc07-0525Search in Google Scholar PubMed

101. Lastra-Gonzalez G, Manrique-Acevedo C, Sowers JR. New trends in insulin resistance: the role of mineralocorticoids. J Cardiometab Syndr 2007;2:233–4.10.1111/j.1559-4564.2007.06170.xSearch in Google Scholar PubMed

102. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293:H2009–23.10.1152/ajpheart.00522.2007Search in Google Scholar PubMed

103. Feraco A, Armani A, Mammi C, Fabbri A, Rosano GM, Caprio M. Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol 2013;137:99–106.10.1016/j.jsbmb.2013.02.012Search in Google Scholar PubMed

104. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009;308:53–62.10.1016/j.mce.2009.02.005Search in Google Scholar PubMed

105. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268–75.10.1126/science.3037703Search in Google Scholar PubMed

106. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21:2185–94.10.1096/fj.06-7970comSearch in Google Scholar PubMed

107. Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, Touyz RM. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 2011;58:479–88.10.1161/HYPERTENSIONAHA.110.168872Search in Google Scholar PubMed

108. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012;59:1069–78.10.1161/HYPERTENSIONAHA.111.190223Search in Google Scholar PubMed

109. Corbould A. Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. Horm Metab Res 2007;39:915–8.10.1055/s-2007-993156Search in Google Scholar PubMed

110. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008;117:2253–61.10.1161/CIRCULATIONAHA.107.748640Search in Google Scholar PubMed PubMed Central

111. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009;84:164–72.10.1093/cvr/cvp191Search in Google Scholar PubMed

112. Hwang MH, Yoo JK, Luttrell M, Kim HK, Meade TH, English M, Segal MS, Christou DD. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond) 2013;125:513–20.10.1042/CS20130200Search in Google Scholar PubMed PubMed Central

113. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457–63.10.1210/jc.2006-0736Search in Google Scholar PubMed

114. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006;55:1645–52.10.1016/j.metabol.2006.07.025Search in Google Scholar PubMed

115. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006;91:2214–7.10.1210/jc.2005-1718Search in Google Scholar PubMed

116. Kraus D, Jäger J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005;37:455–9.10.1055/s-2005-870240Search in Google Scholar PubMed

117. Torpy DJ, Bornstein SR, Taylor W, Tauchnitz R, Gordon RD. Leptin levels are suppressed in primary aldosteronism. Horm Metab Res 1999;31:533–6.10.1055/s-2007-978789Search in Google Scholar PubMed

118. Haluzík M, Sindelka G, Widimský J Jr, Prázný M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 2002;16:41–5.10.1038/sj.jhh.1001292Search in Google Scholar PubMed

119. Kamari Y, Shimoni N, Koren F, Peleg E, Sharabi Y, Grossman E. High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rats: the role of the renin-angiotensin-aldosterone system. J Hypertens 2010;28:95–101.10.1097/HJH.0b013e3283325eeeSearch in Google Scholar PubMed

120. Lely AT, Krikken JA, Bakker SJ, Boomsma F, Dullaart RP, Wolffenbuttel BH, Navis G. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. J Clin Endocrinol Metab 2007;92:1821–6.10.1210/jc.2006-2092Search in Google Scholar PubMed

121. Flynn C, Bakris GL. Interaction between adiponectin and aldosterone. Cardiorenal Med 2011;1:96–101.10.1159/000327023Search in Google Scholar PubMed PubMed Central

122. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975–81.10.1253/circj.68.975Search in Google Scholar PubMed

123. Cao Y, Tao L, Yuan YX, Jiao XY, Lau WB, Wang YJ, Christopher T, Lopez B, Chan L, Goldstein B, Ma XL. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009;46:413–9.10.1016/j.yjmcc.2008.10.014Search in Google Scholar PubMed PubMed Central

124. Shargorodsky M, Boaz M, Goldberg Y, Matas Z, Gavish D, Fux A, Wolfson N. Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis? Int J Obes (Lond) 2009;33:553–8.10.1038/ijo.2009.37Search in Google Scholar PubMed

125. Li FY, Cheng KK, Lam KS, Vanhoutte PM, Xu A. Cross-talk between adipose tissue and vasculature: role of adiponectin. Acta Physiol (Oxf) 2011;203:167–80.10.1111/j.1748-1716.2010.02216.xSearch in Google Scholar PubMed

126. Li P, Zhang XN, Pan CM, Sun F, Zhu DL, Song HD, Chen MD. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res 2011;43:464–9.10.1055/s-0031-1277226Search in Google Scholar PubMed

127. Jiang H, Ye XP, Yang ZY, Zhan M, Wang HN, Cao HM, Xie HJ, Pan CM, Song HD, Zhao SX. Aldosterone directly affects apelin expression and secretion in adipocytes. J Mol Endocrinol 2013;51:37–48.10.1530/JME-13-0025Search in Google Scholar PubMed

128. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161–7.10.1161/HYPERTENSIONAHA.107.095489Search in Google Scholar PubMed

129. Park YM, Lim BH, Touyz RM, Park JB. Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. J Korean Med Sci 2008;23:1039–45.10.3346/jkms.2008.23.6.1039Search in Google Scholar PubMed PubMed Central

130. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776–83.10.7326/0003-4819-150-11-200906020-00005Search in Google Scholar PubMed PubMed Central

131. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409–15.10.1172/JCI117936Search in Google Scholar PubMed PubMed Central

132. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745–51.10.1152/ajpendo.2001.280.5.E745Search in Google Scholar PubMed

133. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001;286:327–34.10.1001/jama.286.3.327Search in Google Scholar PubMed

134. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494–505.10.1172/JCI26498Search in Google Scholar PubMed PubMed Central

135. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111–9.10.1172/JCI25102Search in Google Scholar PubMed PubMed Central

136. Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004;59:359–93.10.1210/rp.59.1.359Search in Google Scholar

137. Kumari M, Chandola T, Brunner E, Kivimaki M. A nonlinear relationship of generalized and central obesity with diurnal cortisol secretion in the Whitehall II study. J Clin Endocrinol Metab 2010;95:4415–23.10.1210/jc.2009-2105Search in Google Scholar

138. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s disease of the omentum”? Lancet 1997;349:1210–3.10.1016/S0140-6736(96)11222-8Search in Google Scholar

139. Chanson P, Salenave S. Metabolic syndrome in Cushing’s syndrome. Neuroendocrinology 2010;92(Suppl 1):96–101.10.1159/000314272Search in Google Scholar PubMed

140. Lee MJ, Pramyothin P, Karastergiou K, Fried SK. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta 2014;1842:473–81.10.1016/j.bbadis.2013.05.029Search in Google Scholar PubMed PubMed Central

141. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166–70.10.1126/science.1066285Search in Google Scholar PubMed

142. Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)-a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:255–62.10.2174/1568008033340135Search in Google Scholar PubMed

143. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53:931–8.10.2337/diabetes.53.4.931Search in Google Scholar PubMed

144. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005;54:1023–31.10.2337/diabetes.54.4.1023Search in Google Scholar PubMed PubMed Central

145. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein J. The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol 2010;204:153–64.10.1677/JOE-09-0292Search in Google Scholar PubMed

146. Gu P, Xu A. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Rev Endocr Metab Disord 2013;14:49–58.10.1007/s11154-012-9230-8Search in Google Scholar PubMed

147. Mérial-Kieny C, Lonchampt M, Cogé F, Verwaerde P, Galizzi JP, Boutin JA, Lafontan M, Levens N, Galitzky J, Félétou M. Endothelin-1 inhibits TNF alpha-induced iNOS expression in 3T3-F442A adipocytes. Br J Pharmacol 2003;139:935–44.10.1038/sj.bjp.0705325Search in Google Scholar PubMed PubMed Central

148. Koh EH, Kim M, Ranjan KC, Kim HS, Park HS, Oh KS, Park IS, Lee WJ, Kim MS, Park JY, Youn JH, Lee KU. eNOS plays a major role in adiponectin synthesis in adipocytes. Am J Physiol Endocrinol Metab 2010;298:E846–53.10.1152/ajpendo.00008.2010Search in Google Scholar PubMed